Navigation Links
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
Date:9/13/2011

NEW YORK, Sept. 13, 2011 /PRNewswire/ -- IMMUNE Pharmaceuticals, an emerging leader in the development of Antibody based Therapeutics for the treatment of inflammatory diseases and cancer, today announced the appointment of Dr. Alan Harris, M.D., Ph.D., to the position of Chief Medical Officer.  In this new position, Dr. Harris will play a pivotal  role in the development of Bertilimumab, IMMUNE's phase II ready fully human monoclonal antibody in development for Crohn's Disease and Ulcerative Colitis,  as well as  NanoMAb development candidates in oncology. NanoMAbs are next generation bio- therapeutics with targeting mAbs conjugated to drug loaded nanoparticules.

"Alan brings impressive credentials and pharmaceutical clinical  development experience to the IMMUNE team," said Dr. Daniel Teper, Founder, Chairman of the Board and Chief Executive Officer of IMMUNE Pharmaceuticals.  "We are delighted to attract someone of Alan's caliber to our growing organization.  He will be a tremendous asset and play a critical role as IMMUNE evolves into a clinical stage company."

Dr. Harris led the clinical development of Novartis' somatostatin analogue, octreotide (Sandostatin®), for the treatment of gastrointestinal tumors and endocrine diseases.  More than 20 years after its introduction, Sandostatin remains a leading therapy, with sales reaching $1.4 billion in 2010.  Dr. Harris has also held leadership positions overseeing the clinical development of small molecules and biologics as Vice President of Research at Schering Plough, Therapeutic Head of Endocrinology at Pfizer, Senior Vice President of R & D and Chief Medical Officer at NPS Pharmaceuticals.

Dr. Harris is currently Adjunct Professor in the Department of Pharmacology at NYU Medical Center in New York, and was previously Associate Professor of Medicine at UCLA Medical School and Director of the Division of Clinical Pharmacology
'/>"/>

SOURCE IMMUNE Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
4. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
8. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
9. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
10. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... 9, 2011 /PRNewswire-USNewswire/ – CoMeD – On Friday, May ... filed an amendment to regulate vaccines containing mercury in ... buy, sell, manufacture, deliver, import, administer or distribute any ... or inorganic mercury per milliliter for children younger than ...
... 2011 Kinex Pharmaceuticals, LLC announced today that Dr. Allen ... decided to step aside as CEO. Dr. ... from a start-up biotechnology company with only a technology platform ... pre-IND to phase 2 developments. The recent collaboration established with ...
Cached Medicine Technology:Florida Legislature Refuses to Limit Mercury in Vaccines 2Florida Legislature Refuses to Limit Mercury in Vaccines 3The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer 2The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer 3
(Date:8/29/2014)... Indosoft, Inc. , a leading provider of scalable ... most advanced contact center product, Q-Suite 5.7.7. This ... as updates to existing aspects of its popular ... presentation side has received an update with the incorporation ... This WYSIWYG editor allows admins to easily add advanced ...
(Date:8/29/2014)... Denver, Colorado (PRWEB) August 29, 2014 ... perfect body is never easy. , According to ... dreamed body might be simpler than imagined with the ... reveals that Shapeshifter Yoga can be an amazingly effective ... Yoga review indicates that this new program is really ...
(Date:8/29/2014)... 29, 2014 Daily Gossip reveals in its ... a new method of naturally curing this disease. , ... to a permanent cure in only one week. This is ... need to make huge sacrifices. , Moreover, with this ... the symptoms of sciatica in just 8 minutes. , ...
(Date:8/29/2014)... Los Angeles, CA (PRWEB) August 29, 2014 ... site that connects the industry’s most notable plastic ... recommended doctors that write about cutting edge techniques ... checked to ensure they contain the most reliable ... select the right cosmetic treatment.     , Cosmetic Town ...
(Date:8/29/2014)... August 29, 2014 The Department of ... final rule (file code CMS–0052–P) today allowing healthcare providers ... 2011 Edition Certified EHR Technology (CEHRT) or a combination ... (EPs) who have not been able to fully implement ... in 2014 can continue to use 2011 Edition CEHRT, ...
Breaking Medicine News(10 mins):Health News:Indosoft Releases Q-Suite 5.7.7 2Health News:Shapeshifter Yoga Review Reveals Kris Fondran's New Body Shaping and Fat Loss Program 2Health News:Stop Sciatica in 8 Minutes Review Exposes Steven Guo's Complete Sciatica Cure 2Health News:Cosmetic Town Is Now Connecting Patients with Qualified Cosmetic Specialists 2Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2
... fuel consumption besides the deleterious effects it has on health.// ... 940 million more gallons of gas into their vehicles than ... now become roughly two dozen pounds heavier which amounted to ... at $3 for a gallon of gas. ,These ...
... reasons to prove that two migratory birds, the common wood ... vulnerable and prone to infection with the highly virulent H5N1 ... the deadly bird flu. ,In an effort to ... Avian flu which had most parts of the world reeling ...
... Food and Drug Administration gave its approval for Tyzeka ... treatment of chronic Hepatitis B// (HBV). Clinical studies have shown ... is usually well tolerated. ,Hepatitis B is a ... every year. It is a serious illness and around 5000 ...
... study published on Tuesday, the younger brains of teens ... ,However, the researchers found that this enhanced ... that could result in permanent damage to the under-developed ... rats as substitutes for teen drinkers.,The previous studies by ...
... Advisory Committee on Immunization Practices has made the recommendation on ... zoster) virus.// ,The vaccine is called Zostavax (Merck& ... May. It has a live virus several times more potent ... ,Shingles is an extremely painful rash caused by the ...
... Maputo – Trials for the malaria vaccine are underway in ... vaccine in the market by 2010. The production// of the ... deputy health minister, Aida Libombo, while addressing a gathering of ... be available by 2010 if the tests in Manhica (north ...
Cached Medicine News:Health News:Brain development in teens curbed by alcohol tolerance 2